LakePharma announces its cGMP microBiomanufacturing Center is now operational
SAN CARLOS, Calif. and BOSTON, Dec. 18, 2018
SAN CARLOS, Calif. and BOSTON, Dec. 18, 2018 /PRNewswire/ -- LakePharma, Inc., the leading US-based biologics company specializing in antibody & protein engineering, cell line development, and protein production, announced today that their cGMP microBiomanufacturing™ Center is now commercially manufacturing plasmid DNA at their Hopkinton, MA location, which is in close proximity to the Cambridge and Boston areas.
LakePharma collaborates on projects at all stages of biologics development from discovery, preclinical to cGMP manufacturing for Phase I/II clinical trials. With its microBiomanufacturing Center operational, the company provides fully integrated solutions from vector design to manufacturing of non-GMP and fully compliant GMP-grade plasmid DNA.
"LakePharma has been active in producing plasmid DNA at research scale in California and Massachusetts for many years now. It is gratifying that the company has advanced to GMP-compliant production suite," commented Hua Tu, LakePharma's CEO. "LakePharma has been relentless in capability expansion and service integration to provide our valued clients with end-to-end solutions. The launch of the GMP-compliant suite dedicated to plasmid DNA manufacturing is the latest example of this commitment. We will continue to build and develop our microBiomanufacturing Center in Hopkinton to meet our client's GMP production needs."
In addition to an experienced and dedicated team, LakePharma designs productive and efficient processes to manufacture plasmid DNA in their cGMP facility. Plasmid DNA can be produced in batch sizes from 10 mg to multi-gram scale. LakePharma also utilizes single-use technologies to reduce potential cross-contamination issues.
"Our teams can support accelerated delivery times and specific process controls for our clients. The average biotech industrial experience for our manufacturing teams is over 10 years. We are excited to bring that experience and capability to serving our clients," commented Frank Zhang, Director of LakePharma's Manufacturing Science and Technology.
For more information, please visit www.lakepharma.com/GMP-plasmid-manufacturing.
LakePharma is the leading US-based biologics company specializing in antibody engineering, antibody discovery, molecular engineering, protein chemistry, bioexpression, biofunction, bioprocessing, bioanalytics, process development (upstream, downstream, and scale-up), microBiomanufacturing and cGMP biorepository services. LakePharma focuses on integrated platforms to support projects throughout the drug discovery and development processes. LakePharma offers dedicated client services and sophisticated software to provide real-time access to project data via a secure cloud-based portal.
Senior Director, Business Development
View original content to download multimedia:http://www.prnewswire.com/news-releases/lakepharma-announces-its-cgmp-microbiomanufacturing-center-is-now-operational-300767779.html
SOURCE LakePharma, Inc.